BioAv Cancer Research Results
BioAv, bioavailability: Click to Expand ⟱
| Source: |
| Type: measurement |
Bioavailability (usually in %) absorbed by the body.
|
Cerv, Cervical Cancer: Click to Expand ⟱
Scientific Papers found: Click to Expand⟱
| - |
in-vitro, |
Cerv, |
HeLa |
|
|
|
- |
in-vitro, |
Liver, |
HepG2 |
|
|
|
- |
in-vitro, |
BC, |
MCF7 |
|
|
|
- |
in-vitro, |
Lung, |
A549 |
|
|
|
- |
in-vitro, |
Nor, |
HUVECs |
|
|
|
eff↑, Dose∅, *BioAv↑, selectivity↑, TumCP↓, Casp↑, PTEN↑, TSC1↑, mTOR⇅, Akt↓, PDK1↓, E6↓, E7↓, DNAdam↑, ROS↑, *BioAv↓, *BioEnh↑, *Half-Life∅,
TumCP↓, Apoptosis↑, RadioS↑, ChemoSen↑, *antiOx↑, *Inflam↓, *Bacteria↓, *AntiViral↑, *AntiDiabetic↑, *neuroP↑, AntiCan↑, TumCG↓, TumCI↓, TumCCA↑, cl‑PARP↑, selectivity↑, CycB/CCNB1↓, CDK1↓, p‑cDC2↓, p‑ERK↓, p‑p38↑, p‑JNK↑, MMP9↓, TIMP1↑, BioAv↓, BioAv↑, Half-Life↑,
*Inflam↓, *antiOx↑, *neuroP↑, *AntiDiabetic↑, *Bacteria↓, AntiTum↑, CSCs↓, ROS↑, TumAuto↑, Apoptosis↑, ChemoSen↑, RadioS↑, BioAv↓, *cardioP↑, *ROS↓, *LDH↓, TumCP↓, TRAIL⇅, TumCMig↓, EMT↓, NF-kB↓, P53↑, Casp3↑, NOTCH↓, CSCs↓, angioG↓, VEGF↓, Ki-67↓, CD31↓, TRAILR↑, MMP↓, BioAv↓, BioAv↑,
| - |
in-vitro, |
Cerv, |
HeLa |
|
|
|
- |
in-vitro, |
sarcoma, |
S180 |
|
|
|
tumCV↓, ROS↑, *GutMicro↑, BioAv↑, other↝, Dose↝,
| - |
in-vitro, |
Cerv, |
HeLa |
|
|
|
- |
in-vitro, |
Nor, |
1321N1 |
|
|
|
*ROS↓, *BioAv↑, LC3II↑, LAMP1?, TumAuto↑, TFEB↑, ROS↑, eff↓,
Showing Research Papers: 1 to 5 of 5
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
ROS↑, 4,
Mitochondria & Bioenergetics(tgid=3) ⓘ
MMP↓, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
PDK1↓, 1,
Cell Death(tgid=5) ⓘ
Akt↓, 1, Apoptosis↑, 2, Casp↑, 1, Casp3↑, 1, p‑JNK↑, 1, p‑p38↑, 1, TRAIL⇅, 1, TRAILR↑, 1,
Transcription & Epigenetics(tgid=7) ⓘ
other↝, 1, tumCV↓, 1,
Autophagy & Lysosomes(tgid=9) ⓘ
LC3II↑, 1, TFEB↑, 1, TumAuto↑, 2,
DNA Damage & Repair(tgid=10) ⓘ
DNAdam↑, 1, P53↑, 1, cl‑PARP↑, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
CDK1↓, 1, CycB/CCNB1↓, 1, TumCCA↑, 1,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
p‑cDC2↓, 1, CSCs↓, 2, EMT↓, 1, p‑ERK↓, 1, mTOR⇅, 1, NOTCH↓, 1, PTEN↑, 1, TumCG↓, 1,
Migration(tgid=13) ⓘ
CD31↓, 1, Ki-67↓, 1, LAMP1?, 1, MMP9↓, 1, TIMP1↑, 1, TSC1↑, 1, TumCI↓, 1, TumCMig↓, 1, TumCP↓, 3,
Angiogenesis & Vasculature(tgid=14) ⓘ
angioG↓, 1, VEGF↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
NF-kB↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↓, 3, BioAv↑, 3, ChemoSen↑, 2, Dose↝, 1, Dose∅, 1, eff↓, 1, eff↑, 1, Half-Life↑, 1, RadioS↑, 2, selectivity↑, 2,
Clinical Biomarkers(tgid=22) ⓘ
E6↓, 1, E7↓, 1, Ki-67↓, 1,
Functional Outcomes(tgid=23) ⓘ
AntiCan↑, 1, AntiTum↑, 1,
Total Targets: 57
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
antiOx↑, 2, ROS↓, 2,
Core Metabolism/Glycolysis(tgid=4) ⓘ
LDH↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
Inflam↓, 2,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↓, 1, BioAv↑, 2, BioEnh↑, 1, Half-Life∅, 1,
Clinical Biomarkers(tgid=22) ⓘ
GutMicro↑, 1, LDH↓, 1,
Functional Outcomes(tgid=23) ⓘ
AntiDiabetic↑, 2, cardioP↑, 1, neuroP↑, 2,
Infection & Microbiome(tgid=24) ⓘ
AntiViral↑, 1, Bacteria↓, 2,
Total Targets: 15
Scientific Paper Hit Count for: BioAv, bioavailability
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:29 Cells:% prod#:% Target#:792 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid
Home Page